HopeStage
Back to all studies
CompletedNCT01152697

Adherence Support With Long-Acting Antipsychotic Injections

About this titleRead the official source — NCT01152697
Medication studyAges 18+United StatesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 18 years.

Listed locations
ClevelandSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJune 2010
Recruitment status
Completed
Enrollment listed in the registry
30
Sponsor
University Hospitals Cleveland Medical Center
Sponsor type
University
Study type
Behavioral
Intervention type
Behavioural, Drug
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT01152697
Official title
Show the full official title

A Prospective Trial of Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic (CAE-L) in Individuals With Schizophrenia or Schizoaffective Disorder at Risk for Treatment Non-adherence and for Homelessness

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Cleveland

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University Hospitals Cleveland Medical Center, a university.

Did this study involve medication?

Yes. The study involved medication, including haloperidol decanoate and haloperidol.

Who was this study for?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies